| 0.2619 0.262 (-2.89%) | 04-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.02  |
1-year : | 1.5 |
| Resists | First : | 0.88 |
Second : | 1.28 |
| Pivot price | 0.88 |
|||
| Supports | First : | 0.21 |
Second : | 0.18 |
| MAs | MA(5) : | 0.51 |
MA(20) : | 0.89 |
| MA(100) : | 2.25 |
MA(250) : | 9.62 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.6  |
D(3) : | 11.2 |
| RSI | RSI(14): 28.9 |
|||
| 52-week | High : | 35 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ASBP ] has closed above bottom band by 4.1%. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.33 - 0.33 | 0.33 - 0.33 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.26 - 0.26 | 0.26 - 0.26 |
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Tue, 21 Apr 2026
LCID, ASBP, WLDS Stocks Hit 52-Week Lows: What Drove The Selloff? - Stocktwits
Mon, 20 Apr 2026
Aspire says its $30M auto supplier deal won't need another stock sale - Stock Titan
Fri, 17 Apr 2026
ASBP - Finviz
Fri, 17 Apr 2026
ASBP Stock Price, Quote & Chart | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Thu, 16 Apr 2026
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.36e+006 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 401 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -43 % |
| Return on Assets (ttm) | 403.5 % |
| Return on Equity (ttm) | -446.9 % |
| Qtrly Rev. Growth | 6200 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -116 |
| Qtrly Earnings Growth | -16.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 430840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|